Skip Ribbon Commands
Skip to main content
Menu

Prof Tan Chee Kiat

​MBBS (Spore), FRCP Edin, FAMS

Senior Consultant

Specialty: Gastroenterology & Hepatology

Sub-specialties: Hepatology, Liver Cancer, Liver Transplantation, Viral Hepatitis, Diagnostic Gastroscopy

Clinical Appointments

  • Senior Consultant Gastroenterology & Hepatology Singapore General HospitalSingapore General Hospital

Profile

Prof Tan Chee Kiat graduated from the Faculty of Medicine, National University of Singapore in 1984.  He became a Member of the Royal College of Physicians, United Kingdom [MRCP (UK)] in 1989 and Fellow of the Royal College of Physicians, Edinburgh [(FRCP (Edin)] in 1998.  He is also a Fellow of the Academy of Medicine, Singapore in Gastroenterology [FAMS (Gastroenterology)] since 1995. He has trained in Hepatology and Liver Transplantation at the Mayo Clinic, Rochester, Minnesota, USA.  He is a fully trained gastroenterologist and besides General Hepatology, his areas of interests are Liver Cancer, Viral Hepatitis and Liver Transplantation. He has set up a nationwide web-based database for hepatocellular carcinoma.

Education

  • ​MBBS (Spore)
  • FRCP Edin
  • FAMS

Professional Appointments and Committee Memberships

Awards

  • Singapore Cancer Syndicate Grant for development of National Liver Cancer Registry (2004-2009)
  • SGH Excellent Publication Award 2003
  • Glaxo Research Institute Fellow's Award for basic research 1994
  • Ministry of Health Manpower Development Program award 1993-1994
  • Singapore Government Local Merit Scholarship for Medicine (1979-1984)

Research Interests

Publications and Research Trials

  • ​TT Chang, CL Lai, S Han, KH Han, S Gordon, YC Chao, CK Tan, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histologic damage.  Hepatology (in press).
  • S Purushotham, PEJ Chang, H Rumpel, IHC Kee, RTH Ng, PKH Chow, CK Tan, RV Ramanujan. Thermoresponsive core-shell magnetic nanoparticles for combined modalities of cancer therapy. Nanotechnology 2009; 20: 305101.  doi:10.1088/09574484/20/30/305101, published 7 July 2009.
  • PE Chang, WC Ong, HF Lui, CK Tan. Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome.  J Gastroenterol 2008; 43:881-888.
  • PE Chang, HF Lui, YP Chau, KH Lim, WM Yap, CK Tan, WC Chow. Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate transaminases platelet ratio index. Aliment Pharmacol Ther 2008; 28:51-61.
  • Tan CK, Law NM, Ng HS, Machin D.  A simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation.  J Clin Oncol 2003; 21(12):2294-2298.
  • Chow PKH, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized trial. Hepatology 2002; 36(5):1221-1226.
  • Tan CK, Ho MSJ. Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation. Liver Transpl 2001; 7(5):461-465.
  • Tan CK, PKH Chow, Findlay M, et al. The use of tamoxifen in hepatocellular carcinoma – A review and paradigm shift. J Gastroenterol Hepatol 2000; 15(7): 725-9.
  • Tan CK, PV Podila, JE Taylor, et al. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition.    Gastroenterology 1995; 108(6): 1908-16.
  • Tan CK, Gores GJ, Steers JL, et al. Orthotopic liver transplantation for preoperative early-stage hepatocellular carcinoma. Mayo Clin Proc 1994; 69: 509-14.

Research Trials